Xu, R., Wang, F., Wang, Z., Peng, J., Liang, X., Cheng, Y., Deng, Y., Chen, K., Zhang, M., Zhang, J., Wang, W., Cao, B., Jin, Y., Sun, M., Lin, Y., Luo, S., Li, Z., Yang, L., Wang, Q., Zhu, J. (2025). Updated efficacy and subgroup analysis of first-line serplulimab plus bevacizumab and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.170